Stem Cell Therapeutics Corp. Announces Regenerative Medicine Panel Discussion led by Dr. Allen Davidoff

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT") announced today that Dr.
Allen Davidoff, VP of Product Development, will be moderating a meeting and
panel discussions as part of a public forum discussing "Demystifying innovations
and advancing the commercialization of Alberta's emerging technologies" in
Regenerative Medicine.


This public forum will be held in Calgary this evening from 7:00-9:30pm at the
Kerby Seniors Centre. The Alberta Council of Technologies ("ABCtech") and
BioAlberta will also be co-hosting a second, similar public forum tomorrow
evening in Edmonton.


About the ABCTech and BioAlberta Public Forums (http://www.abctech.ca/): Each of
the two public events is designed to engage Albertans in a patient-focused
dialogue to demystify stem cell therapies. The forums have been designed to
resolve three objectives: 1) to increase public and patient awareness of stem
cell therapies, its implications on health care delivery and their potential in
preventing and treating degenerative diseases, 2) to establish Alberta's
bio-tech sector as a world leader in the development of stem cell technologies,
and 3) to prepare Alberta for the early delivery of stem cell therapy. 


About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public
biotechnology company (TSX VENTURE:SSS) focused on the development and
commercialization of drug-based therapies to treat central nervous system
diseases. SCT is a leader in the development of therapies that utilize drugs to
stimulate a patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The Company's
extensive patent portfolio of owned and licensed intellectual property supports
the potential expansion into future clinical programs in numerous neurological
diseases such as traumatic brain injury, multiple sclerosis, Huntington's
disease, Alzheimer's disease, and ALS.


These securities have not been registered under the United States Securities Act
of 1933, as amended, or the securities laws of any state, and may not be offered
or sold within the United States or to, or for the account or benefit of U.S.
persons unless an applicable exemption from U.S. registration requirements is
available.


Except for historical information, this press release may contain
forward-looking statements, which reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.